Compare Dollar Tree, Inc. (DLTR) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs GeneDx Holdings Corp — how do they compare? Dollar Tree, Inc. trades at $118.58 (market cap $22.26B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Dollar Tree, Inc. is far larger — about 11× GeneDx Holdings Corp's market cap, and Dollar Tree, Inc. is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dollar Tree, Inc. for 58 Days and GeneDx Holdings Corp for 19 Days on average.
| DLTR | WGS | |
|---|---|---|
Market Cap | $22.26B | $2.02B |
Volume | 2,317,428 | 734,640 |
Sector | Consumer Staples | Health |
52-Week High | $141.21 | $167.51 |
52-Week Low | $86.80 | $34.51 |
Typical Hold Time | 58 Days | 19 Days |
Enterprise Value | $28.87B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $118.64, up 2.01% with bullish technical signals and strong earnings beats in recent quarters. The stock shows robust fundamentals with a P/E of 14.54, ROE of 45.87%, and positive cash flow trends. Recent news highlights strategic initiatives and institutional buying interest, though margin pressures and tariff volatility remain concerns.
DLTR presents a compelling investment case with improving earnings outlook and attractive valuation metrics. However, investors should weigh the strong analyst consensus (53% buy ratings, $139.33 target) against margin risks and recent insider selling activity that could signal near-term headwinds.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
